title: Reply: To PMID 25105313.
authors.affiliation: *Department of Ophthalmology, Tongliao City Hospital, Tongliao, China †State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangzhou, China ‡The Royal Victorian Eye and Ear Hospital, Melbourne, Australia §Department of Ophthalmology, General Hospital of Guangzhou Military Command of PLA, Guangzhou, China ¶Department of Ophthalmology, The First Affiliated Hospital of Kunming Medical University, Kunming, China **Aier School of Ophthalmology, Central South University, Changsha, China.
authors.forename: Qingyun
authors.initials: Q
authors.lastname: Liu
authors.forename: Yijun
authors.initials: Y
authors.lastname: Hu
authors.forename: Honghua
authors.initials: H
authors.lastname: Yu
authors.forename: Ling
authors.initials: L
authors.lastname: Yuan
authors.forename: Jie
authors.initials: J
authors.lastname: Hu
authors.forename: Alp
authors.initials: A
authors.lastname: Atik
authors.forename: Shibo
authors.initials: S
authors.lastname: Tang
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy*; D008297:Male; D014222:Triamcinolone Acetonide / Q000627:therapeutic use*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D014222:Triamcinolone Acetonide